Denosumab and Raloxifene Cardiovascular Risk

By using the EHR database, we first identified patients aged 30–89 years at the time of initiation of denosumab or raloxifene between 1 January 2003 and 31 December 2017 to be included in the study. To develop the new user cohort, only patients with ≥1-year records before treatment initiation were included in the study. To assess the risk of CVD, patients were excluded with history of stroke, myocardial infarction, heart failure, and cancer. Patients receiving procedures for cardiovascular diseases, including percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG), were also identified before treatment initiation and excluded from analyses. Because raloxifene was used in women, male patients were excluded from the analysis. Operational definitions and codes for disease conditions and procedures are listed in Table S1.

Free full text: Click here

Liu T.C., Hsu C.N., Lee W.C., Wang S.W., Huang C.C., Lee Y.T., Fu C.M., Chen J.B, & Li L.C. (2023). Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women. Pharmaceuticals, 16(2), 222.

Publication 2023

Cancer Cardiovascular diseases Coronary artery bypass surgery Denosumab Heart failure Male Myocardial infarction Patients Percutaneous coronary intervention Raloxifene Stroke Women

Corresponding Organization : Chang Gung University

Other organizations : Kaohsiung Medical University

Top 5 similar protocols

Variable analysis

independent variables

Treatment with denosumab or raloxifene

dependent variables

Risk of cardiovascular disease (CVD), including stroke, myocardial infarction, and heart failure

control variables

Patients aged 30-89 years at the time of treatment initiation
Patients with ≥1-year records before treatment initiation
Patients without history of stroke, myocardial infarction, heart failure, and cancer
Patients not receiving procedures for cardiovascular diseases, including percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) before treatment initiation
Female patients (male patients were excluded from the analysis)

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!